Please assess the completion status of the following clinical trial:

Trial Title: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Core Study~* Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including~  1. Mini Mental State Examination score equal to or greater than 24~ 2. Clinical Dementia Rating (CDR) global score of 0.5~ 3. CDR Memory Box score of 0.5 or greater~* Impaired episodic memory confirmed by a list learning task~* Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both~Extension Phase~• Participants who complete the Core Study~Exclusion Criteria:~Core Study~* Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation~* Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD~* Participants with a history of seizures within 5 years of Screening~* History of transient ischemic attacks or stroke within 12 months of Screening~* Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)~* Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years~* Have any contraindications to magnetic resonance imaging (MRI) scanning or~  1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI~ 2. Exhibit other significant pathological findings on brain MRI.~* Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)~* Results of laboratory tests conducted during Screening that are outside the following limits:~  1. Absolute lymphocyte count below the lower limit of normal (LLN)~ 2. Thyroid stimulating hormone above normal range~ 3. Abnormally low Vitamin B12 levels~* Participants at increased risk of infection~* Have received any live vaccine/live attenuated vaccine in the 3 months before randomization~* Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy~* Any other clinically significant abnormalities~* Severe visual or hearing impairment~* A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction \[QTcF\] greater than 450 milliseconds \[ms\])~* Malignant neoplasms within 5 years of Screening~* Known or suspected history of drug or alcohol abuse~* Taking prohibited medications, which must be reviewed with the Investigator~* Have participated in a recent clinical study~Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Core Study: Elenbecestat 50 mg (Type: EXPERIMENTAL): Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
- Core Study: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
- Open-label Extension Phase: Elenbecestat 50 mg (Type: EXPERIMENTAL): Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).